Publicaciones científicas
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
28-dic-2022
| Revista: Cancer Discovery
Ignacio Melero 1 2 3 4 , Miguel F Sanmamed 1 2 3 4 , Javier Glez-Vaz 1 2 , Carlos Luri-Rey 1 2 , Jun Wang 5 , Lieping Chen 6
Abstract
CD137 (4-1BB) is a costimulatory receptor of T and natural killer lymphocytes whose activity can be exploited in cancer immunotherapy strategies as discovered 25 years ago.
Following initial attempts that met unacceptable toxicity, new waves of constructs acting agonistically on CD137 are being developed in patients, offering signs of clinical and pharmacodynamic activity with tolerable safety profiles.
CITA DEL ARTÍCULO Cancer Discov. 2023 Mar 1;13(3):552-569. doi: 10.1158/2159-8290.CD-22-1029
Nuestros autores
Codirector
Servicio de Inmunología e Inmunoterapia
Sede Pamplona
Especialista
Departamento de Oncología Médica
Sede Pamplona